Search

everythinglearnresearchcommunity

for

Search:↓

Genetically repaired stem cells may treat certain genetic diseases, Th17 cells are key in fighting systemic fungal infections, hair loss in AGA is due to progenitor cell loss, and α-synuclein transfer might contribute to Parkinson's disease progression.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Removing certain hair follicle stem cells worsens skin reactions to allergens.

Researchers developed a 3D skin model with its own immune and blood vessel cells to better understand skin health and disease.

The document doesn't provide a clear conclusion or detailed findings about the impact of certain cells on cancer treatment.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Lgr5+ stem cells do not cause skin tumors.

MicroRNAs are crucial in controlling cell signaling, affecting cancer and tissue regeneration.

Blood stem cells are diverse, influenced by many factors, and understanding them is key for progress in regenerative medicine.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

CD34+ hair follicle stem cells can become melanin-producing cells for treating skin conditions.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Certain immune cells may cause hair loss by reacting to stressed hair follicles.

Advances in mechanobiology and immunology could lead to scarless wound healing.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Age-related immune changes significantly affect disease development in other systems.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Thymic mesenchymal cells have unique gene expression that supports their specific functions in the thymus.

A new type of nerve cell involved in itch perception was discovered.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Stem cell behavior varies with stimuli, and lineage changes can happen without affecting stem cell division.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.